Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP High-Risk Medulloblastoma Trial
NL-OMON54193Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Oct 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin, etoposide, thiotepa, vincristine, lomustine and 3 more in medulloblastoma, sponsored by University of Birmingham. Primary endpoint: Event-free survival. Started Oct 2022; status: recruiting.
02
Drugs
carboplatinetoposidethiotepavincristinelomustine
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NL-OMON54193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54193.